These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37936454)

  • 1. Drug Delivery for Ocular Allergy: Current Formulation Design Strategies and Future Perspectives.
    Regu VR; Swain RP; Subudhi BB
    Curr Pharm Des; 2023; 29(33):2626-2639. PubMed ID: 37936454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanocrystal for ocular drug delivery: hope or hype.
    Sharma OP; Patel V; Mehta T
    Drug Deliv Transl Res; 2016 Aug; 6(4):399-413. PubMed ID: 27165145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.
    Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A
    Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic nanoemulsions in ophthalmic drug administration: Concept in formulations and characterization techniques for ocular drug delivery.
    Singh M; Bharadwaj S; Lee KE; Kang SG
    J Control Release; 2020 Dec; 328():895-916. PubMed ID: 33069743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept.
    Patel N; Thakkar V; Metalia V; Baldaniya L; Gandhi T; Gohel M
    Drug Dev Ind Pharm; 2016 Sep; 42(9):1406-23. PubMed ID: 26716613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel in situ gelling ophthalmic drug delivery system based on gellan gum and hydroxyethylcellulose: Innovative rheological characterization, in vitro and in vivo evidence of a sustained precorneal retention time.
    Destruel PL; Zeng N; Seguin J; Douat S; Rosa F; Brignole-Baudouin F; Dufaÿ S; Dufaÿ-Wojcicki A; Maury M; Mignet N; Boudy V
    Int J Pharm; 2020 Jan; 574():118734. PubMed ID: 31705970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular delivery systems for topical application of anti-infective agents.
    Duxfield L; Sultana R; Wang R; Englebretsen V; Deo S; Rupenthal ID; Al-Kassas R
    Drug Dev Ind Pharm; 2016 Jan; 42(1):1-11. PubMed ID: 26325119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comprehensive Review on the Role of Polymers in Ocular Drug Delivery.
    Paramjot ; Wadhwa S; Sharma A; Singh SK; Vishwas S; Kumar R; Singh S; Dua K; Chellappan DK; Gupta G
    Curr Drug Deliv; 2024; 21(1):16-37. PubMed ID: 36627785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of poloxamers in ophthalmic pharmaceutical formulations: an overview.
    Almeida H; Amaral MH; Lobão P; Sousa Lobo JM
    Expert Opin Drug Deliv; 2013 Sep; 10(9):1223-37. PubMed ID: 23688342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced topical corticosteroids delivery to the eye: A trade-off in strategy choice.
    Shen L; Fang G; Tang B; Zhu Q
    J Control Release; 2021 Nov; 339():91-113. PubMed ID: 34560157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies.
    Mofidfar M; Abdi B; Ahadian S; Mostafavi E; Desai TA; Abbasi F; Sun Y; Manche EE; Ta CN; Flowers CW
    Int J Pharm; 2021 Sep; 607():120924. PubMed ID: 34324989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticles in Ocular Drug Delivery Systems for Topical Administration: Promises and Challenges.
    Almeida H; Amaral MH; Lobao P; Frigerio C; Sousa Lobo JM
    Curr Pharm Des; 2015; 21(36):5212-24. PubMed ID: 26412360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymer-based carriers for ophthalmic drug delivery.
    Imperiale JC; Acosta GB; Sosnik A
    J Control Release; 2018 Sep; 285():106-141. PubMed ID: 29964135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent updates on ocular disease management with ophthalmic ointments.
    Bisen AC; Dubey A; Agrawal S; Biswas A; Rawat KS; Srivastava S; Bhatta RS
    Ther Deliv; 2024; 15(6):463-480. PubMed ID: 38888757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
    Babizhayev MA
    Drug Test Anal; 2012 Jun; 4(6):468-85. PubMed ID: 21416634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent patents on ophthalmic nanoformulations and therapeutic implications.
    Ako-Adounvo AM; Nagarwal RC; Oliveira L; Boddu SH; Wang XS; Dey S; Karla PK
    Recent Pat Drug Deliv Formul; 2014; 8(3):193-201. PubMed ID: 25262835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ gelling systems for ocular drug delivery.
    Ahmed B; Jaiswal S; Naryal S; Shah RM; Alany RG; Kaur IP
    J Control Release; 2024 Jul; 371():67-84. PubMed ID: 38768662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.
    Lanier OL; Manfre MG; Bailey C; Liu Z; Sparks Z; Kulkarni S; Chauhan A
    AAPS PharmSciTech; 2021 Mar; 22(3):107. PubMed ID: 33719019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.